MDLUX2: Drawing a Fuller Picture
Luxembourg’s new molecular diagnostics initiative seeks to better personalize cancer care
Michael Schubert | | Quick Read
MDLUX2 has a bold overall mission: to improve the treatment outcomes of cancer patients in Luxembourg, with a particular emphasis on rare and complex cancers (1). Continuing on from a previous initiative, the program also aims to determine whether or not molecular diagnostics are feasible and cost-effective as a routine part of cancer care; at the moment, such tests are not paid for by public health insurance, so MDLUX2 is vital in establishing their value to patients.
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine